COVID-19 and Anticoagulants

19 December 2022

Recent evidence shows potentially significant drug interactions may occur between COVID-19 treatments, including Paxlovid, Lagevrio and Veklury and anticoagulants. Broadly speaking:

Lagevrio – there are no reported significant drug interactions with anticoagulants, particularly with Direct Oral Anticoagulants (DOACs) at this time.

Paxlovid – there are important interactions with anticoagulants, particularly with DOACs and also with warfarin.

Veklury – may increase or decrease the anticoagulant effect of warfarin.  Such interactions can impact on laboratory monitoring of anticoagulant use and the safe use of anticoagulants. 

It is advised that drug interactions are checked if patients are commenced on the above-listed COVID-19 treatments. Refer to the product information sheets; additionally, the following links provide information on potentially significant drug interactions: 

It is recommended that you consult with a pharmacist as well as the appropriate clinical services if potentially significant drug interactions are identified.

General News

27
Mar

RCPA Pathology Update 2024

SA Pathology was a proud supporter of the inaugural RCPA Pat...

27
Mar

The Future of Diagnosis: How QUP Can Revolutionise Patient Care

Quality use of pathology (QUP) centres on the appropriate an...

1
Mar

Syphilis: The Great Imitator

While cases of syphilis (Treponema pallidum) are on the rise...

1
Mar

Genomic partnership delivering life - changing insights

In 2016, genomic sequencing was gaining traction across the ...

1
Mar

Lead poisoning - know the symptoms

In the early 1990’s Australia banned the use of lead in item...